|
Please note that the Pregnancy Registry for Varicella Zoster Virus Containing Vaccines is now CLOSED to new enrollment.
Merck and the CDC have jointly agreed to discontinue the Merck/CDC Pregnancy Registry for Varicella-Zoster Virus (VZV) Containing Vaccines (VARIVAX®, ProQuad® and ZOSTAVAX®). Data collected for the pregnancy registry for over 17 years for VARIVAX and 6 years for ProQuad and ZOSTAVAX indicate that there have been no signals to indicate a risk of Congenital Varicella Syndrome or pattern of birth defects related to vaccination with the VZV-containing vaccines. Therefore, new patient enrollment was discontinued on October 16, 2013. Follow-up of patients currently enrolled will continue until data from the last patient enrolled are collected or it is determined that the patient is lost to follow-up.
Registry personnel wish to convey their gratitude to the women and health care providers who reported cases of vaccination during pregnancy and completed registry questionnaires. Their contributions have allowed for ongoing surveillance of the VZV-containing vaccines.
The Company continues to seek information and pregnancy outcomes on patient exposures to the VZV-containing vaccines during pregnancy or within three months prior to conception. For questions related to exposure to VARIVAX, ProQuad or ZOSTAVAX during pregnancy or to report new cases of exposure to VARIVAX, ProQuad or ZOSTAVAX during pregnancy or within three months of conception, please contact Merck’s call center at 1-877-888-4231.
|
